Blinatumomab: a Bispecific T Cell Engager (BiTE) Antibody Against CD19/CD3 for Refractory Acute Lymphoid Leukemia

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2015 Sep 5

PMID 26337639

Citations 81

Authors

Jingjing Wu

Jiaping Fu

Mingzhi Zhang

Delong Liu

Affiliations

Soon will be listed here.

Abstract

Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.

Citing Articles

Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies.

Choi S, Lee J, Ko S, Hong S, Jin H Biomol Ther (Seoul). 2024; 32(6):708-722.

PMID: 39448393 PMC: 11535297. DOI: 10.4062/biomolther.2024.146.

Activation of T Lymphocytes with Anti-PDL1-BiTE in the Presence of Adipose-Derived Mesenchymal Stem Cells (ASCs).

Moeinzadeh L, Ramezani A, Mehdipour F, Yazdanpanah-Samani M, Razmkhah M Biomed Res Int. 2024; 2023:7692726.

PMID: 39282109 PMC: 11401667. DOI: 10.1155/2023/7692726.

Ponatinib-review of historical development, current status, and future research.

Kantarjian H, Chifotides H, Haddad F, Short N, Loghavi S, Jabbour E Am J Hematol. 2024; 99(8):1576-1585.

PMID: 38727135 PMC: 11233239. DOI: 10.1002/ajh.27355.

Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.

Dabkowska A, Domka K, Firczuk M Front Immunol. 2024; 15:1363102.

PMID: 38638442 PMC: 11024268. DOI: 10.3389/fimmu.2024.1363102.

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.

Li T, Niu M, Zhou J, Wu K, Yi M Cell Commun Signal. 2024; 22(1):179.

PMID: 38475778 PMC: 10935874. DOI: 10.1186/s12964-024-01562-5.

References

Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel P, Schwenkenbecher J . A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000; 95(6):2098-103. View

Carter R, Wang Y, Brooks S . Role of CD19 signal transduction in B cell biology. Immunol Res. 2002; 26(1-3):45-54. DOI: 10.1385/IR:26:1-3:045. View

Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T . Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia. 2003; 17(5):900-9. DOI: 10.1038/sj.leu.2402890. View

Del Nagro C, Otero D, Anzelon A, Omori S, Kolla R, Rickert R . CD19 function in central and peripheral B-cell development. Immunol Res. 2005; 31(2):119-31. DOI: 10.1385/IR:31:2:119. View

Brandl C, Haas C, dArgouges S, Fisch T, Kufer P, Brischwein K . The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. 2007; 56(10):1551-63. PMC: 11030660. DOI: 10.1007/s00262-007-0298-z. View

Rowe J, Goldstone A . How I treat acute lymphocytic leukemia in adults. Blood. 2007; 110(7):2268-75. DOI: 10.1182/blood-2007-05-038950. View

Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M . Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother. 2007; 30(8):798-807. DOI: 10.1097/CJI.0b013e318156750c. View

Carter R, Myers R . Germinal center structure and function: lessons from CD19. Semin Immunol. 2008; 20(1):43-8. PMC: 2346595. DOI: 10.1016/j.smim.2007.12.007. View

Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S . Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891):974-7. DOI: 10.1126/science.1158545. View

10.

dArgouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A . Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res. 2008; 33(3):465-73. DOI: 10.1016/j.leukres.2008.08.025. View

11.

Gokbuget N, Hoelzer D . Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2008; 46(1):64-75. DOI: 10.1053/j.seminhematol.2008.09.003. View

12.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle P, Zugmaier G . Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009; 50(6):886-91. DOI: 10.1080/10428190902943077. View

13.

Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A . Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2010; 25(1):181-4. DOI: 10.1038/leu.2010.239. View

14.

Younes A, Bartlett N, Leonard J, Kennedy D, Lynch C, Sievers E . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363(19):1812-21. DOI: 10.1056/NEJMoa1002965. View

15.

Nagorsen D, Baeuerle P . Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011; 317(9):1255-60. DOI: 10.1016/j.yexcr.2011.03.010. View

16.

Topp M, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S . Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29(18):2493-8. DOI: 10.1200/JCO.2010.32.7270. View

17.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

18.

Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73. PMC: 3393096. DOI: 10.1126/scitranslmed.3002842. View

19.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz R, Lambert J . SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011; 17(20):6448-58. DOI: 10.1158/1078-0432.CCR-11-0485. View

20.

Advani A . Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2012; 9(10):776-7. View